Jessica Boklan

910 total citations
30 papers, 467 citations indexed

About

Jessica Boklan is a scholar working on Molecular Biology, Hematology and Neurology. According to data from OpenAlex, Jessica Boklan has authored 30 papers receiving a total of 467 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 15 papers in Hematology and 10 papers in Neurology. Recurrent topics in Jessica Boklan's work include Acute Myeloid Leukemia Research (11 papers), Neuroblastoma Research and Treatments (10 papers) and Acute Lymphoblastic Leukemia research (8 papers). Jessica Boklan is often cited by papers focused on Acute Myeloid Leukemia Research (11 papers), Neuroblastoma Research and Treatments (10 papers) and Acute Lymphoblastic Leukemia research (8 papers). Jessica Boklan collaborates with scholars based in United States, Canada and Malaysia. Jessica Boklan's co-authors include Tanya Trippett, Aru Narendran, Lia Gore, Claudia P. Miller, Shan Gao, Joya Chandra, Howard M. Katzenstein, Cynthia E. Herzog, R.J. Arceci and Margaret E. Macy and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Jessica Boklan

27 papers receiving 461 citations

Peers

Countries citing papers authored by Jessica Boklan

Since Specialization

Citations

This map shows the geographic impact of Jessica Boklan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jessica Boklan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jessica Boklan more than expected).

Fields of papers citing papers by Jessica Boklan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jessica Boklan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jessica Boklan. The network helps show where Jessica Boklan may publish in the future.

Co-authorship network of co-authors of Jessica Boklan

This figure shows the co-authorship network connecting the top 25 collaborators of Jessica Boklan. A scholar is included among the top collaborators of Jessica Boklan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jessica Boklan. Jessica Boklan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors 2025 ·Cancers ·Jessica Boklan, Anne‐Marie Langevin, Kevin Bielamowicz, Kathleen Neville, Tanya Trippett, Valerie I. Brown, Steven G. DuBois, (unknown), (unknown), (unknown), Aru Narendran, Norman J. Lacayo	0
2	Treatment of relapsed/refractory severe aplastic anemia in children: Evidence‐based recommendations 2024 ·Pediatric Blood & Cancer ·Kristin A. Shimano, Ghadir Sasa, Larisa Broglie, Nicholas J. Gloude, Kasiani C. Myers, Taizo A. Nakano, Anjali Sharathkumar, Jennifer Rothman, María A. Pereda, (unknown), Anupama Narla, Catherine McGuinn, Bonnie Lau, Amy E. Geddis, Yigal Dror, Jill L. O. de Jong, Paul Castillo, S. W. Allen, Jessica Boklan	1
3	Treatment of newly diagnosed severe aplastic anemia in children: Evidence‐based recommendations 2024 ·Pediatric Blood & Cancer ·Kristin A. Shimano, Jennifer Rothman, S. W. Allen, Paul Castillo, Jill L. O. de Jong, Yigal Dror, Amy E. Geddis, Bonnie Lau, Catherine McGuinn, Anupama Narla, (unknown), María A. Pereda, Anjali Sharathkumar, Ghadir Sasa, Taizo A. Nakano, Kasiani C. Myers, Nicholas J. Gloude, Larisa Broglie, Jessica Boklan	3
4	Dual functionality of the antimicrobial agent taurolidine which demonstrates effective anti-tumor properties in pediatric neuroblastoma 2019 ·Investigational New Drugs ·(unknown), Chunfen Zhang, Olga Kovalchuk, Jessica Boklan, Tanya Trippett, Aru Narendran	6
5	Outcomes of Hematopoietic Cell Transplantation in Patients with Germline SAMD9/SAMD9L Mutations 2019 ·Biology of Blood and Marrow Transplantation ·Ibrahim Ahmed, Midhat S. Farooqi, Mark T. Vander Lugt, Jessica Boklan, Melissa J. Rose, (unknown), Brandon M. Triplett, Kenneth Lieuw, Blachy J. Dávila Saldaña, Christine M. Smith, Jason R. Schwartz, Rakesh K. Goyal	29
6	Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia 2019 ·Blood ·Chunfen Zhang, (unknown), Satbir Thakur, (unknown), Olena M. Vaske, Lauren Sanders, Jessica Boklan, Victor Lewis, (unknown), Olga Kovalchuk, Norman J. Lacayo, Aru Narendran, Kevin Bielamowicz	0
7	Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib 2018 ·Targeted Oncology ·(unknown), Aarthi Jayanthan, Yibing Ruan, (unknown), Jessica Boklan, Tanya Trippett, Aru Narendran	6
8	Pediatric Chronic Myeloid Leukemia Presenting With Extreme Thrombocytosis Simulating Essential Thrombocythemia 2018 ·Journal of Pediatric Hematology/Oncology ·Jessica Boklan, Alexandra Walsh, (unknown), Leon Su, (unknown), Kristian T. Schafernak	2
9	A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03) 2017 ·Pediatric Blood & Cancer ·Todd M. Cooper, Edward Allan R. Sison, Sharyn D. Baker, Lie Li, (unknown), Tanya Trippett, Lia Gore, Margaret E. Macy, Aru Narendran, Keith J. August, Michael J. Absalon, Jessica Boklan, Jessica A. Pollard, Daniel Magoon, Patrick A. Brown	62
10	A Multicenter, First-in-Pediatrics, Phase 1, Pharmacokinetic and Pharmacodynamic Study of Ridaforolimus in Patients with Refractory Solid Tumors 2013 ·Clinical Cancer Research ·Lia Gore, Tanya Trippett, Howard M. Katzenstein, Jessica Boklan, Aru Narendran, Amy Smith, Margaret E. Macy, (unknown), (unknown), Rachel M. Squillace, Christopher Turner, Frank G. Haluska, Michael L. Nieder	19
11	Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS 2013 ·Blood ·Todd M. Cooper, Sharyn D. Baker, (unknown), Tanya Trippett, Lia Gore, Aru Narendran, Keith J. August, Michael J. Absalon, Jessica Boklan, Jessica A. Pollard, Daniel Magoon, Edward Allan R. Sison, Patrick A. Brown	4
12	A multi‐center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors 2012 ·Pediatric Blood & Cancer ·Margaret E. Macy, (unknown), James A. Whitlock, Stephen P. Hunger, Jessica Boklan, Aru Narendran, Cynthia E. Herzog, R.J. Arceci, Rochelle Bagatell, Tanya Trippett, Uwe Christians, (unknown), S. Percy Ivy, Lia Gore	8
13	Phase I dose‐escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias 2012 ·Pediatric Blood & Cancer ·(unknown), Lia Gore, Rebecca M. Ricklis, Jessica Boklan, Todd M. Cooper, Aru Narendran, (unknown), Tammy Scott, R.J. Arceci	8
14	Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML) 2012 ·Blood ·Lia Gore, Margaret E. Macy, Françoise Méchinaud, Aru Narendran, Frank Alvaro, Carola A.S. Arndt, Phillip Barnette, Jessica Boklan, Todd M. Cooper, Laura Martín, (unknown), Peter G. Tarassoff, Mark M. Jones, Soheil Meshinchi, R.J. Arceci	2
15	A multicenter, first-in-pediatrics phase I study of ridaforolimus (AP23573, MK-8669) in patients (pts) with refractory solid tumors. 2010 ·Journal of Clinical Oncology ·Lia Gore, Tanya Trippett, Howard M. Katzenstein, Jessica Boklan, (unknown), (unknown), Margaret E. Macy, Narayana I. Narasimhan, (unknown), Michael L. Nieder	4
16	Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium 2009 ·Journal of Clinical Oncology ·Tanya Trippett, Cynthia E. Herzog, James A. Whitlock, Johannes Wolff, John F. Kuttesch, Rochelle Bagatell, Stephen P. Hunger, Jessica Boklan, Amy Smith, R.J. Arceci, Howard M. Katzenstein, Christopher Harbison, Xiaofei Zhou, Haolan Lu, Christiane Langer, Martin R. Weber, Lia Gore	38
17	Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells 2007 ·Leukemia Research ·Shan Gao, (unknown), Claudia P. Miller, Jessica Boklan, Joya Chandra	52
18	Potentiation of Reactive Oxygen Species Is a Marker for Synergistic Cytotoxicity of MS-275 and 5-Azacytidine in Leukemic Cells. 2007 ·Blood ·Shan Gao, Claudia P. Miller, Jessica Boklan, Joya Chandra	2
19	Little patients, losing patience: pediatric cancer drug development 2006 ·Molecular Cancer Therapeutics ·Jessica Boklan	31
20	LUNG TRANSPLANTATION AFTER ALLOGENEIC MARROW TRANSPLANTATION IN PEDIATRIC PATIENTS 2001 ·Transplantation ·John A. Heath, Geoffrey Kurland, Thomas L. Spray, Nancy A. Kernan, (unknown), Joel A. Brochstein, Alfred P. Gillio, Jessica Boklan, (unknown), Farid Boulad	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact